Rab Prinjha
Chief Research & Development Officer Curve Therapeutics
Rab has spent the last 25 years building and executing R&D portfolio delivery performance. He brings deep experience in successful small molecule, nucleic acid and biopharma R&D, spanning oncology, neuroscience, immunology, and epigenetics.
Prior to joining Curve, Rab was Head of the Immunology Research Unit and Immunology Network sponsor at GSK, leading the development of several clinical candidates and new targets. He previously led the Epigenetics group and was responsible for target selection and validation along with coordinating academic collaborations with leaders in the oncology, neuroscience, immunology, and epigenetics therapy areas.
Rab currently holds positions on the Scientific Advisory Boards of MRC Human Genetics Unit Edinburgh and Enhance3D Genomics and is an Elected Fellow of Academy of Medical Sciences and Elected Senior Fellow Royal Society of Biology.
Seminars
- Exploring the unique advantages of cyclic peptides and their growing importance in addressing challenging therapeutic targets.
- Understanding when and why mammalian display systems are critical for identifying and optimising peptides against complex targets.
- Showcasing Curve Therapeutics’ innovative platform and recent progress in expanding the possibilities of cyclic peptide drug discovery and development.
